| SCHEDULE OF SEGMENT INFORMATION |
SCHEDULE
OF SEGMENT INFORMATION
| |
|
2024 |
|
|
2023 |
|
| |
|
For the Three Months Ended
January 31, |
|
| |
|
2024 |
|
|
2023 |
|
| Net loss: |
|
|
|
|
|
|
|
|
| CAR-T Therapeutics |
|
$ |
(1,525 |
) |
|
$ |
(911 |
) |
| Cancer Vaccines |
|
|
(1,756 |
) |
|
|
(958 |
) |
| Anti-Viral Therapeutics |
|
|
- |
|
|
|
(482 |
) |
| Other |
|
|
(9 |
) |
|
|
(3 |
) |
| Total |
|
$ |
(3,290 |
) |
|
$ |
(2,354 |
) |
| Net loss |
|
$ |
(3,290 |
) |
|
$ |
(2,354 |
) |
| |
|
|
|
|
|
|
|
|
| Total operating costs and expenses |
|
$ |
3,609 |
|
|
$ |
2,556 |
|
| Less non-cash share-based compensation |
|
|
(1,260 |
) |
|
|
(1,063 |
) |
| Operating costs and expenses excluding non-cash share-based compensation |
|
$ |
2,349 |
|
|
$ |
1,493 |
|
Operating costs and expenses excluding non-cash
share based compensation expense: |
|
|
|
|
|
|
|
|
| CAR-T Therapeutics |
|
$ |
1,128 |
|
|
$ |
598 |
|
| Cancer Vaccines |
|
|
1,213 |
|
|
|
588 |
|
| Anti-Viral Therapeutics |
|
|
- |
|
|
|
305 |
|
| Other |
|
|
8 |
|
|
|
2 |
|
| Total |
|
$ |
2,349 |
|
|
$ |
1,493 |
|
| Operating costs and expenses excluding non-cash share based compensation |
|
$ |
2,349 |
|
|
$ |
1,493 |
|
| |
|
January 31,
2024 |
|
|
October 31,
2023 |
|
| Total assets: |
|
|
|
|
|
|
|
|
| CAR-T Therapeutics |
|
$ |
12,124 |
|
|
$ |
7,523 |
|
| Cancer Vaccines |
|
|
13,162 |
|
|
|
17,215 |
|
| Anti-Viral Therapeutics |
|
|
- |
|
|
|
700 |
|
| Other |
|
|
86 |
|
|
|
84 |
|
| Total |
|
$ |
25,372 |
|
|
$ |
25,522 |
|
| Total assets |
|
$ |
25,372 |
|
|
$ |
25,522 |
|
|